Details : Under the agreement, Celltrion and LISCure intend to develop, oral LBPs, microbiome-based therapies, for Parkinson's disease. LISCure advances brain-target bacterial exosome technology for neurodegenerative diseases based on its platform technology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 20, 2023
SK Biopharmaceuticals, BIORCHESTRA Collaborate to Develop miRNA-Targeted Therapeutics
Details : Under the collaboration agreement, BIORCHESTRA, that develops RNA therapeutics for neurodegenerative diseases, will be responsible for target discovery, selection, and synthesis via its in-house technology by using antisense oligonucleotides.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 01, 2022